Search
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs...
Jul 21
Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline
He describes the benefits of prime editing, walks us through human proof-of-concept data that was announced in a patient with Chronic...
Jul 17
Kailera Therapeutics' partner Hengrui announced positive p3 results for its GLP1/GIP agonist in China - biotech veteran and Kailera CEO Ron Renaud walks us through the company's obesity space strategy
He describes why Kailera chose to in-license a GLP1/GIP specifically, and describes where he sees this asset placing in the competitive...
Jul 16
Southampton, UK based Curve Therapeutics believes its mammalian cell-based 'Microcycle' platform is a better way to do drug discovery - lead programs from it target HIF-1/HIF-2 and ATIC
Co-Founder and CEO Simon Kerry discusses being in Southampton, and why he believes the 'Microcycle' platform beats screening in...
Jul 15
Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)
Jorge Santos da Silva walks us through the scientific design of the molecule, which is a nanobody that binds to IL-17A, IL-17F, and...
Jul 10
KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks
Ben Palleiko is asked about the company's take on headlines that were in the news during the FDA review of the drug, and he describes the...
Jul 7
AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery
Co-Founder & CEO Peter Fedichev describes why he believes reading the amino acid sequences that have been written into the human genome...
Jun 30
ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features
He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same...
Jun 27
Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year
Josh Cohen and Justin Klee walk us through the lead program, avexitide, which is a GLP-1 antagonist and is currently in a pivotal study...
Jun 25
Oxford, UK based Pathios Therapeutics is targeting GPR65 for cancer, a signaling pathway that becomes active in the low pH tumor microenvironment and causes immunosuppression and high angiogenesis
CEO Paul Higham describes the biology of GPR65 inhibition, something that pharma companies have previously tried to do, and explains how...
Jun 24
AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets
Co-Founder Linda Goodman describes the product and the numerous components that go into the scoring.
Jun 20
AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences
Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an...
Jun 19
Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited
An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University...
Jun 18
BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward
CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial...
Jun 18
BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy
Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for,...
Jun 18
Cardiff-based Draig Therapeutics launched today in the neuro space with a total investment of $140 million, with lead program DT-101, an AMPA receptor PAM, ready for P2 in Major Depressive Disorder
Professor Simon Ward of Cardiff University’s Medicines Discovery Institute, and Scientific Co-founder and CSO Draig, describes the...
Jun 17
BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs
He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short...
Jun 17
BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs....
Jun 17
BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal
CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS),...
Jun 17
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple...
Jun 16
.png){kind=logo}
